Patient advocacy advancing psychedelic science.
Apollo Pact is working with researchers, patients, Congress, government agencies & stakeholders to make medical psychedelic treatments affordable, accessible & scalable. We are striving to innovate the healthcare landscape by utilizing science and technology.
PATIENT SAFETY
Apollo Pact's founder, Jon Kostas, credits this therapy with curing his alcohol use disorder, after trying all other available treatments. While Apollo Pact works to advance psychedelic science and medical research, we advise against the use of these powerful compounds outside of clinical settings.
Psychedelics are illegal in the U.S. and the only legal way to access psychedelic therapies to treat health disorders is through clinical trials. You can find if a clinical trial is near you at www.clinicaltrials.gov or email hello@apollopact.org for assistance.
1 in 5 American adults experience a mental health issue.
Apollo Pact, Inc. is a medical research and education 501(c)(3) nonprofit. Our mission is to address the mental illness epidemic by relying on science & research.
Our founders were clinical participants in NYU & Johns Hopkins studies. When they realized how well psilocybin medical treatment worked, they knew they had to help others in desperate need access it.
What is psilocybin?
Psilocybin is a compound in psychedelic mushrooms. Research suggests psilocybin-assisted therapy can be more effective than standard treatments for addiction, depression, anxiety, PTSD, and other mental and behavioral health disorders.
Medical Research
Just like our team members, more and more people are starting to participate in clinical trials. NYU, Johns Hopkins, Yale, are just a few universities conducting research. Contact us if you or someone you know are interested in participating.
Education & Advocacy
Stigma is a big hurdle to overcome in legalizing psilocybin medical treatment. Not only does psilocybin have a stigma attached to it, but the illnesses it can treat also have stigmas, such as depression and addiction. By objectively showing data and research of these clinical trials - and how it compares to conventional therapy and pharmaceutical prescriptions - psilocybin will have a more favorable public opinion. We can start to turn the tide of psilocybin-related stigma and showcase its vast potential to provide true and lasting mental health benefits.
“This was the only treatment that worked for me. I haven’t craved a drink since 2015.”
— Jon Kostas on 60 Minutes